Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
Johnson & Johnson has discontinued its Mosaico clinical trial that aimed to protect against HIV after its Phase 3 study revealed the regiment was safe but ineffective.
Verily, the life sciences subsidiary of Google parent company Alphabet, is laying off 15% of its workforce just months after raising $1 billion in a funding round.
The U.S. Food and Drug Administration (FDA) has launched a new pilot program that aims to streamline medical device development, increase predictability and reduce the time from concept to commercialization.
Verily, a life science company that was formerly a division of Google X, has raised $1 billion in a funding round led by Alphabet, parent company to Google.
